Clinical trials
Resistance clinical trials
Below are recruiting resistance clinical trials, each written for real people, not researchers. We’re tracking 1,199 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05636605Recruiting
Study lung cancer biology and why immunotherapy stops working
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Yiwu, ZhejiangAges 18–80 - NCT01994057Recruiting
Looking back at EGFR-targeted pills for lung cancer
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
Guangzhou, GuangdongAges 18–85 - NCT05452213RecruitingPhase 4
Study patterns of ribociclib response and resistance in breast cancer
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Erlangen, BavariaAges 18 years+ - NCT05534672RecruitingPhase 3
Rapamycin for drug-resistant seizures in tuberous sclerosis
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
LodzAges 3 months–50 years - NCT05224401RecruitingPhase 3
Oral antibiotic step-down for ESBL bladder infections
This Phase 3 trial tests whether switching from short-term IV antibiotics to an oral antibiotic combo is safe and effective for ESBL urine infections. It may help you avoid staying on IV antibiotics as long, if your bacteria are the right match.
HelsingborgAges 18–130 - NCT05046483Recruiting
Blood sugar study after a new heart attack
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
Düsseldorf, North Rhine-WestphaliaAges 18–80 - NCT05583747Recruiting
Brain stimulation therapy with guidance for treatment-resistant depression
This study tests a type of brain stimulation (guided iTBS) to improve depression when standard antidepressant treatments haven’t helped. It also checks that the treatment is safe for people who can meet the study and scan safety requirements.
Toronto, OntarioAges 18–65 - NCT06061042Recruiting
Time-restricted eating for metabolic health
This study tests whether eating only during a specific time window each day can improve metabolic health in people with obesity and insulin resistance. If you have a high BMI and early signs of diabetes, this trial might help you understand a simple dietary change.
Amsterdam, North HollandAges 50–75 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT02208141Recruiting
Child body growth study with planned surgery
This study follows children’s body growth and fat (adipose) tissue as part of a planned surgical procedure. It aims to improve understanding of how fat tissue develops in childhood and what factors may affect health later.
Leipzig, SaxonyAges Any age - NCT06039787Recruiting
Exercise and Brain Insulin Sensitivity Study
This study checks if exercise training changes how your brain responds to insulin. You will do ergometer (stationary bike) training, and your brain activity will be measured before and after. It's for people who are not very active now and want to see how exercise affects brain metabolism.
TübingenAges 20–65 - NCT04754672Recruiting
Exercise training to improve outcomes in advanced colon cancer
This trial studies whether supervised exercise—either aerobic fitness training or muscle-strength training—can improve outcomes for people with metastatic colorectal cancer. It compares which approach is most helpful and checks whether it’s safe during first-line chemotherapy.
's-HertogenboschAges 18 years+ - NCT02844049Recruiting
Quality-of-life study for treatment-resistant OCD with DBS
This study looks at whether deep brain stimulation (DBS) helps people with long-term, treatment-resistant obsessive-compulsive disorder (OCD), and how it affects quality of life. It involves careful screening because it’s meant for OCD that has not responded to several medication and therapy attempts.
CréteilAges 18–69 - NCT06166199Recruiting
High-intensity interval training for lupus patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can help people with systemic lupus erythematosus (SLE, an autoimmune disease). It aims to see if this type of exercise is safe and improves symptoms.
Stockholm, HuddingeAges 18 years+ - NCT05246345Recruiting
Study for chronic lymphocytic leukemia after venetoclax failure
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
AmiensAges 18 years+ - NCT07864207RecruitingPhase 1/Phase 2
Study of IDP-121 for small cell lung cancer that stopped responding to platinum
This trial tests a new drug, IDP-121, alone or with another chemo drug, for people with small cell lung cancer that came back after initial treatment. The goal is to see if it can shrink tumors and help people live longer.
BarcelonaAges 18 years+ - NCT07871110RecruitingPhase 2
New pill combined with hormone therapy for advanced prostate cancer
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Fuzhou, FujianAges 18 years+ - NCT06228677Recruiting
Catecholamine levels during adrenal artery embolization
This trial measures hormone levels in blood during a procedure to treat high blood pressure caused by an adrenal gland problem. It may help doctors understand how the body responds during treatment.
Chengdu, SichuanAges 18 years+ - NCT07874139Recruiting
Study on antibiotic resistance in chronic lung disease
This study looks at antibiotic resistance in people with chronic lung disease by checking their respiratory samples. It aims to understand how resistance develops and help improve treatment.
Ann Arbor, MichiganAges Any age - NCT06236789Recruiting
Ifosfamide for men with advanced prostate cancer
This trial is studying whether the chemotherapy drug ifosfamide (given with mesna to protect the bladder) can help men whose prostate cancer has spread and is no longer controlled by hormone therapy. It is for men who have already tried the chemotherapy docetaxel.
SeoulAges 19 years+ - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT07856368Recruiting
Magnetic brain stimulation for persistent voices
This study tests a non-invasive brain stimulation treatment called transcranial magnetic stimulation (TMS) to reduce persistent auditory hallucinations (hearing voices) that haven't improved with antipsychotic medication. It may help people who continue to hear voices despite trying several medications.
ZurichAges 18–65
Hear when a new Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistance?
- Yes. Clin2 currently lists 1,199 recruiting resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.